SEI Investments
AXSM icon

SEI Investments’s Axsome Therapeutics AXSM Stock Holding History

SEI Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Buy
70,064
+22,464
+47% +$3.88M 0.01% 1040
2025
Q4 		$8.69M Sell
47,600
-527
-1% -$73.6K 0.01% 1121
2025
Q3 		$5.85M Buy
48,127
+4,178
+10% +$471K 0.01% 1240
2025
Q2 		$4.59M Buy
43,949
+8,220
+23% +$870K 0.01% 1304
2025
Q1 		$4.17M Sell
35,729
-12,501
-26% -$1.42M 0.01% 1342
2024
Q4 		$4.08M Sell
48,230
-131
-0.3% -$12K 0.01% 1389
2024
Q3 		$4.35M Buy
48,361
+7,737
+19% +$675K 0.01% 1354
2024
Q2 		$3.27M Buy
40,624
+4,970
+14% +$368K ﹤0.01% 1410
2024
Q1 		$2.85M Buy
35,654
+2,697
+8% +$226K ﹤0.01% 1464
2023
Q4 		$2.62M Sell
32,957
-28,178
-46% -$1.88M ﹤0.01% 1480
2023
Q3 		$4.27M Sell
61,135
-123,132
-67% -$9.2M 0.01% 1240
2023
Q2 		$13.2M Buy
184,267
+60,158
+48% +$4.44M 0.02% 726
2023
Q1 		$7.66M Sell
124,109
-13,358
-10% -$878K 0.01% 986
2022
Q4 		$10.6M Sell
137,467
-11,322
-8% -$677K 0.02% 707
2022
Q3 		$6.64M Sell
148,789
-13,797
-8% -$689K 0.01% 947
2022
Q2 		$6.23M Buy
162,586
+16,223
+11% +$513K 0.01% 990
2022
Q1 		$6.06M Buy
146,363
+1,909
+1% +$59.2K 0.01% 1005
2021
Q4 		$5.46M Sell
144,454
-1,338
-0.9% -$49.2K 0.01% 1089
2021
Q3 		$4.81M Sell
145,792
-388
-0.3% -$15.1K 0.01% 1102
2021
Q2 		$9.86M Buy
146,180
+2,010
+1% +$121K 0.02% 741
2021
Q1 		$8.16M Buy
144,170
+33,649
+30% +$2.37M 0.02% 767
2020
Q4 		$9M Buy
110,521
+29,098
+36% +$2.18M 0.02% 687
2020
Q3 		$5.8M Buy
81,423
+28,796
+55% +$2.24M 0.02% 802
2020
Q2 		$4.33M Sell
52,627
-1,088
-2% -$83.7K 0.01% 929
2020
Q1 		$3.16M Buy
53,715
+21,432
+66% +$1.75M 0.01% 959
2019
Q4 		$3.34M Buy
32,283
+9,535
+42% +$385K 0.01% 1104
2019
Q3 		$460K Sell
22,748
-4,910
-18% -$126K ﹤0.01% 1931
2019
Q2 		$712K Sell
27,658
-15,987
-37% -$320K ﹤0.01% 1720
2019
Q1 		$621K Buy
+43,645
New +$405K ﹤0.01% 1777

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SEI Investments's AXSM Position: Q1 2026 in Review

SEI Investments increased its Axsome Therapeutics (AXSM) stake by 47% in Q1 2026, buying an estimated $3.88M and bringing the position to 70,064 shares worth $11.8M. The position accounts for 0.01% of the portfolio, ranked #1040.

SEI Investments first reported a position in AXSM in Q1 2019 and has held it in 29 quarters since. The position peaked at $13.2M in Q2 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • SEI Investments held 70,064 shares of Axsome Therapeutics worth $11.8M as of Q1 2026.
  • SEI Investments bought 22,464 Axsome Therapeutics shares in Q1 2026, an estimated $3.88M.
  • Axsome Therapeutics made up 0.01% of SEI Investments's portfolio in Q1 2026, its #1040 holding.
  • SEI Investments first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • SEI Investments's Axsome Therapeutics position peaked at $13.2M in Q2 2023.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.